[
    {
        "ExclusionCriteria": "* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.\n* Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.\n* Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Active infection requiring systemic therapy.\n* Concurrent active hepatitis B and hepatitis C virus infection.\n* History of allogenic tissue/solid organ transplant.\n* Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).\n* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.",
        "NCTId": "NCT05007106"
    }
]